Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).

Benzinga • Dec 8, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Dec 5, 2025

Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet

The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 20, 2025

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Seeking Alpha • Nov 4, 2025

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability

GlobeNewsWire • Nov 4, 2025

Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD) has achieved its randomization target of 555 subjects.

GlobeNewsWire • Nov 4, 2025

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade

The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Oct 30, 2025

Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Ocular Therapeutix (OCUL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research • Oct 24, 2025

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025.

GlobeNewsWire • Oct 7, 2025